[HTML][HTML] Hematological diseases and osteoporosis

A Gaudio, A Xourafa, R Rapisarda, L Zanoli… - International Journal of …, 2020 - mdpi.com
Secondary osteoporosis is a common clinical problem faced by bone specialists, with a
higher frequency in men than in women. One of several causes of secondary osteoporosis is …

Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma

M Gonzalez-Santamarta, G Quinet… - … and Disease: From …, 2020 - Springer
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and …

H Chen, M Li, E Sanchez, CM Soof… - British Journal of …, 2020 - Wiley Online Library
Monocytes polarize into pro‐inflammatory macrophage‐1 (M1) or alternative macrophage‐2
(M2) states with distinct phenotypes and physiological functions. M2 cells promote tumour …

[HTML][HTML] Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in multiple myeloma

K Papadimitriou, N Tsakirakis, P Malandrakis, P Vitsos… - Cancers, 2020 - mdpi.com
Simple Summary In Multiple Myeloma (MM) malignant cells accumulate in the bone marrow
(BM), where they interact with various cell populations. These complex interactions impose …

A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed/refractory multiple myeloma

JR Berenson, J To, TM Spektor, D Martinez… - Clinical Cancer …, 2020 - AACR
Purpose: Ruxolitinib with lenalidomide and dexamethasone shows antimyeloma effects in
vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma cells, and …

[HTML][HTML] Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based …

A Szudy-Szczyrek, R Mlak, M Mielnik, M Szczyrek… - Annals of …, 2020 - Springer
Neutrophils to lymphocytes ratio (NLR) and platelets to lymphocytes ratio (PLR) are
considered as laboratory markers of inflammation. They can be potentially useful in …

[HTML][HTML] Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma

S Akhtar, TA Ali, A Faiyaz, OS Khan, SS Raza… - International Journal of …, 2020 - mdpi.com
Multiple myeloma (MM) is a hematologic disorder of B lymphocytes characterized by the
accumulation of malignant plasma cells (PCs) in the bone marrow. The altered plasma cells …

STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas

R Tamma, G Ingravallo, F Gaudio, T Annese… - Leukemia & …, 2020 - Taylor & Francis
Constitutively activated STAT3 is correlated with more advanced clinical stage and overall
poor survival of diffuse large B-cell lymphoma (DLBCL). The aim of this study was to …

MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma

L Zhang, N Rastgoo, J Wu, M Zhang, M Pourabdollah… - Cancer Letters, 2020 - Elsevier
Abstract Overexpression of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) is
implicated in drug resistance and progression of multiple myeloma (MM). The basis for …

Circulating extracellular vesicle‐associated CD163 and CD206 in multiple myeloma

SL Kvorning, MC Nielsen, NF Andersen… - European Journal of …, 2020 - Wiley Online Library
Abstract Objectives Extracellular vesicles (EVs) are important for intercellular signalling in
cancer. Tumour‐associated macrophages, expressing the haemoglobin‐haptoglobin and …